Atorvastatin Calcium Tablet USP 80 mg, a) 90 count (NDC 67877-0514-90) and b) 500 count (NDC 6787...
FDA Drug Recall #D-1515-2019 — Class II — July 19, 2019
Recall Summary
| Recall Number | D-1515-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 19, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Ascend Laboratories LLC |
| Location | Parsippany, NJ |
| Product Type | Drugs |
| Quantity | a) 5,472 bottles and b) 5,880 bottles |
Product Description
Atorvastatin Calcium Tablet USP 80 mg, a) 90 count (NDC 67877-0514-90) and b) 500 count (NDC 67877-0514-05) bottles, Rx only, Manufactured by: Alkem Laboratories, Ltd, Mumbai INDIA, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ
Reason for Recall
Failed Dissolution Specifications
Distribution Pattern
Product was shipped to wholesalers throughout the United States.
Lot / Code Information
a) Lot# 19140443, exp. date 12/2020, Lot# 19140525, 19140535, exp. date 01/2021 and b) Lot# 19140756, exp. date 12/2020, Lot# 19140757, Lot# 19140758, exp. date 01/2021, Lot# 19141696, Lot# 19141793, exp. date 03/2021
Other Recalls from Ascend Laboratories LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0229-2022 | Class II | Cefixime Capsules 400 mg, 50 capsules bottles, ... | Nov 3, 2021 |
| D-0392-2021 | Class III | Olmesartan Medoxomil Tablets, USP, 20 mg, Rx On... | Apr 29, 2021 |
| D-0264-2021 | Class II | Cephalexin for Oral Suspension, USP 250 mg per ... | Jan 22, 2021 |
| D-0263-2021 | Class II | Cephalexin for Oral Suspension, USP 250 mg per ... | Jan 22, 2021 |
| D-0178-2021 | Class II | Ascend Laboratories, llc Cephalexin for Oral Su... | Dec 17, 2020 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.